The Baby Business and Public Policy
By Marcy Darnovsky,
Science Progress
| 05. 05. 2009
Regulation Can Ensure Well-being and Protect Reproductive Rights
The recent media storm over the in vitro fertilization-induced birth of octuplets has receded into the tabloids and entertainment pages. A second fertility industry scandal that emerged several weeks later-the announcement by a Los Angeles fertility clinic that it would soon offer a program to select embryos not just for sex but also for hair, eye and skin color-has also veered out of the headlines. But the outcry surrounding these events has revealed mounting disquiet about the multi-billion dollar baby business.
The fertility industry's professional societies offer a potential avenue for self-regulation of the field, but their existing recommendations are too often ignored. Other countries regulate assisted reproduction to protect the well-being of all participants, including the children whom it helps create and the families and society into which they are born. Drawing lessons from their successes could help temper the commercial pressures in the U.S. assisted reproduction sector, without in any way diminishing reproductive rights.
The importance of addressing these issues is readily evident. The octuplets story left a mark even on the English language. Google now reports one...
Related Articles
By Jacob M. Apel, The Baltimore Sun | 08.16.2024
By Neha Kondaveeti, The Austin Chronicle | 08.16.2024
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...